Cencora is a medical distribution business based in the US. Cencora shares (COR) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $291.97 – an increase of 0.62% over the previous week. Cencora employs 46,000 staff and has a trailing 12-month revenue of around $303.2 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $291.97 |
|---|---|
| 52-week range | $213.34 - $296.65 |
| 50-day moving average | $270.68 |
| 200-day moving average | $245.27 |
| Wall St. target price | $297.49 |
| PE ratio | 41.4943 |
| Dividend yield | $2.08 (0.75%) |
| Earnings per share (TTM) | $7.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $292.12 from 2025-05-02
| 1 week (2025-04-29) | 0.67% |
|---|---|
| 1 month (2025-04-07) | 6.40% |
| 3 months (2025-02-07) | 17.85% |
| 6 months (2024-11-07) | 17.90% |
| 1 year (2024-05-07) | 28.83% |
|---|---|
| 2 years (2023-05-05) | 77.26% |
| 3 years (2022-05-06) | 89.58% |
| 5 years (2020-05-05) | 253.72% |
Valuing Cencora stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cencora's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cencora's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Cencora shares trade at around 41x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cencora's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1275. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cencora's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Cencora's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.2 billion.
The EBITDA is a measure of a Cencora's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $303.2 billion |
|---|---|
| Operating margin TTM | 0.97% |
| Gross profit TTM | $9.9 billion |
| Return on assets TTM | 2.86% |
| Return on equity TTM | 198.15% |
| Profit margin | 0.46% |
| Book value | $1.17 |
| Market Capitalization | $56.6 billion |
TTM: trailing 12 months
Dividend payout ratio: 20.37% of net profits
Recently Cencora has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Cencora shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Cencora's case, that would currently equate to about $2.08 per share.
While Cencora's payout ratio might seem low, this can signify that Cencora is investing more in its future growth.
Cencora's most recent dividend payout was on 2 March 2025. The latest dividend was paid out to all shareholders who bought their shares by 13 February 2025 (the "ex-dividend date").
Cencora's shares were split on a 2:1 basis on 15 June 2009 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cencora shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cencora shares which in turn could have impacted Cencora's share price.
Over the last 12 months, Cencora's shares have ranged in value from as little as $213.3412 up to $296.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Cencora's is 0.544. This would suggest that Cencora's shares are less volatile than average (for this exchange).
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U. S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .